NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 1, 2013, Pages 3-10

  Wigal, Sharon B ^a   Childress, Ann C ^b   Belden, Heidi W ^c   Berry, Sally A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Center for Psychiatry and Behavioral Medicine Inc   (United States)

^c NextWave Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; NWP 06; PLACEBO; UNCLASSIFIED DRUG;

ACADEMIC ACHIEVEMENT; AFFECT LABILITY; AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EXTENDED DRUG RELEASE; FATIGUE; FEMALE; FLUSHING; HUMAN; INSOMNIA; IRRITABILITY; LOGORRHEA; MALE; MOOD DISORDER; OPTIMAL DRUG DOSE; PRESCHOOL CHILD; PSYCHOPHARMACOTHERAPY; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUSPENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADMINISTRATION, ORAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SUSPENSIONS;

EID: 84874071701     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0073     Document Type: Article

References (29)

1. Adderall XR capsules (prescribing information). Florence, KY: Shire US Inc.; 2010
2. American Academy of Pediatrics: ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128:1007-1020, 2011
3. American Academy of Pediatrics: Clinical practice guideline: Treatment of the school-Aged child with attention-deficit/hyperactivity disorder. Pediatrics 108:1033-1044, 2001
4. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000
5. Armstrong RB, Damaraju CV, Ascher S, Schwarzman L, O'Neill J, Starr HL: Time course of treatment effect of OROS- methylphenidate in children with ADHD. J Atten Disord 16:697-705, 2012
6. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y: Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 62:970-976, 2007
7. Brams M, Muniz R, Childress AC, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez FA, Silva R: A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: Rapid onset of effect. CNS Drugs 22:693-704, 2008
8. Childress AC, Berry SA: The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Postgrad Med 122:1-7, 2010
9. Childress AC, Sallee FR, Berry SA: Single-dose pharmacokinetics of NWP06, an extended-release methylphendate suspension, in children and adolescents with ADHD. Postgrad Med 123:80-88, 2011
10. Daytrana MTS (prescribing information). Miami: Noven Pharmaceuticals, Inc.; 2010
11. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale IV: Checklists, norms, and clinical interpretation. New York: Guilford, 1998
12. Focalin XR capsules (prescribing information). East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010
13. Faraone SV, Buitelaar J: Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-Analysis. Eur Child Adolesc Psychiatry 19:353-364, 2010
14. Food and Drug Administration: Statistical Review and Evaluation: NDA/Serial Number: 202100/0-1 (2011). Reference ID: 2935375. Available at: Www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ UCM274001.pdf Accessed August 8, 2012
15. McCracken JT, Biederman J, Greenhill LL, Swanson JM, McGough JJ, Spencer TJ, Posner K, Wigal S, Pataki C, Zhang Y, Tulloch S: Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 42:673-683, 2003
16. Meltzer EO, Welch MJ, Ostrom NK: Pill swallowing ability and training in children 6 to 11 years of age. Clin Pediatr 45:725-733, 2006
17. Mihajlovic-Madzarevic V: Guidance For Industry-E6 Good Clinical Practice, Consolidated Guidance (Appendix B). In: Clinical Trials Audit Preparation: A Guide for Good Clinical Practice (GCP) Inspections. Hoboken, NJ: John Wiley & Sons, Inc.; 2010; pp.177-178
18. Pliszka SR, Bernet W, Bukstein O, Walter HJ, Arnold V, Beitchman J, Benson RS, Chrisman A, Farchione T, Hamilton J, Keable H, Kinlan J, McClellan J, Rue D, Schoettle U, Shaw JA, Stock S: The American Academy of Child and Adolescent Psychiatry (AACAP) Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attentiondeficit-hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894-921, 2007
19. Polaha J, Dalton WT III, Lancaster BM: Parental report of medication acceptance among youth: Implications for everyday practice. South Med J 101:1106-1112, 2008
20. Quillivant XR (prescribing information). Cupertino, CA: NextWave Pharmaceuticals Inc.; 2012
21. Silva RR, Muniz R, Pestreich L, Brams M, Mao AR, Childress AC, Wang J: Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 47:199-208, 2008
22. Silva RR, Muniz R, Pestreich L, Childress AC, Brams M, Lopez FA, Wang J. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attentiondeficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 16:239-251, 2006
23. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ, COMACS Study Group: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS Study). Pediatrics 113:e206-e216, 2004
24. Vyvanse capsules (prescribing information).Wayne, PA: Shire US Inc.; 2012
25. Wigal T, Brams M, Gasior M, Gao J, Giblin J: Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Postgrad Med 123:169-176 2011
26. Wigal SB, Gupta S, Guinta D, Swanson JM: Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 34:47-53, 1998
27. Wigal SB, Kollins SH, Childress AC, Squires L for the 311 Study Group: A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-Aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 3:17, 2009
28. Wigal SB, Wigal TL: The Laboratory School Protocol: Its origin, use, and new applications. J Atten Disord 10:92-111, 2006
29. Wigal SB, Wigal TL, Kollins SH: Advances in methylphenidate drug delivery systems for ADHD therapy. Advances in ADHD 1:4-7, 2006